Brodalumab's profile for the treatment of patients with moderate-to-severe plaque psoriasis in the Greek everyday clinical practice: Results of the BrIDGE study

Background: BrIDGE, an observational, prospective, multicenter study was designed to provide real- world-evidence data with brodalumab in Greece. Two hundred patients with moderate-to-severe plaque psoriasis were included. At baseline, mean [standard deviation (SD)] Dermatology Life Quality Index (DLQI) score was 12.9 (7.3) and mean (SD) total Psoriasis Area and Severity Index (PASI) score was 17.3 (9.1). Regarding primary endpoint, at Visit 1 (Weeks 12-16), 32% (58/181 patients) achieved PASI100; the respective proportions at Visit 2 (Weeks 24), Visit 3 (Week 52) and Visit 4 (Week 104) were 42% (71/169 patients), 51.3% (80/156 patients) and 65% (89/137 patients). Among patients who achieved PASI100 at Visit 2, 89.6% and 90.2%, respectively, retained PASI100 at Visits 3 and 4. Mean (SD) total PASI score was 3.9 (7.7) at Visit 1, 1.8 (3.6) at Visit 2, 1.5 (4.3) at Visit 3 and 1.0 (2.1) at Visit 4. Forty-four patients discontinued brodalumab treatment. The mean (SD) time to discontinuation was 36.1 (26.4) weeks.